
- Volume 0 0
ADHD DRUGS HAVE NEW WARNINGS
Stimulants that are used totreat attentiondeficit/hyperactivitydisorder(ADHD) will havestronger warninglabels, accordingto an FDA mandate.The labelswill warn againstthe use of the medications in adultsor children with heart problems andwill notify physicians that they cancause 1 child in 1000 to experiencehallucinations. The warnings will befound on Adderall (Shire PharmaceuticalsGroup), Concerta(McNeil Pharmaceuticals), andRitalin (Novartis).
Although these warnings are notas strong as those approved earlierthis year by an FDA advisory committee,they significantly strengthenthe risk information already on thelabels. The warnings are a result ofreports of sudden death in childrentaking the drugs. In some reports,the children were later determinedto have had structural defects of theheart. The new warnings willinclude, in part, "Sudden deaths,strokes, and myocardial infarctionhave been reported in adults takingstimulant drugs at usual doses."
Articles in this issue
about 19 years ago
Equation for Success: Diabetes Medication, Diet, and Exerciseabout 19 years ago
Rx Product Newsabout 19 years ago
OTC Product Newsabout 19 years ago
can you READ these Rxs?about 19 years ago
Juvenile Anabolic Steroid Abuseabout 19 years ago
Compounding Hotlineabout 19 years ago
RESPy AWARD: A Role Model for Pharmacy Studentsabout 19 years ago
Ouch! Time for Flu Shotsabout 19 years ago
Supreme Court Declines to Review Generic Marketing PactsNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.













































































































































































































